News Column

Gemmus Pharma Closes $3.3M Series B Funding to Develop Superior Flu Drug

May 27, 2014



By a News Reporter-Staff News Editor at Life Science Weekly -- Gemmus Pharma Inc. a privately held biotechnology company developing an improved host-targeted treatment for flu, announced that it has closed on a Series B funding. The funding will be used to complete production and toxicology studies for an IND filing by the end of the year (see also Gemmus Pharma Inc.).

The round was funded by a syndicate of angel groups led by the Life Science Angels (LSA) with other members of the syndicate including: BlueTree Allied Angels, The Angels' Forum, Tech Coast Angels and Wilmington Investor Network, as well as several individual investors.

"Gemmus is very pleased to have the support of these experienced angel investors," said Daryl Faulds, PhD, CEO. "We are developing a unique flu treatment that activates the immune system of the host and thus can be effective to combat multiple different strains of the virus. It is a 'best-in-class, first-in-class' oral treatment and this Series B funding will accelerate the filing of our initial IND."

Data on Gemmus' lead candidate, GP1681, will be presented in two posters at the 27th International Conference on Antiviral Research (ICAR) in Raleigh, NC on May 14-15. The poster titled: "Efficacy of the Beraprost Isomer GP1681 for Treating Influenza A Virus Infections in Mice" will be given by Prof. Dale Barnard, Ph.D., of Utah State University. A second poster titled: "Mode of Action of GP1681 as a Therapeutic for Influenza Infections," will be given by Daryl Faulds, Ph.D., Co-Founder and Chief Executive Officer of Gemmus.

The company's candidate, GP1681, is an orally available eicosanoid being developed for the treatment of moderate to severe symptoms of influenza infection. Results of the trials demonstrate that influenza-infected mice which are treated with GP1681 are protected against death compared to placebo-treated mice. Uniquely, findings show that the increased survival is not the result of decreased viral titers but is due to a decrease in respiratory tract inflammation as demonstrated by a decrease in lung weight, lung score and pro-inflammatory cytokines in influenza-infected lungs.

Keywords for this news article include: Gemmus Pharma Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Life Science Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters